Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma

Evidence for efficacy is based on the results from the IMbrave150 study
08 Jun 2020
Anticancer agents & Biologic therapy;  Cancer Immunology and Immunotherapy;  Gastrointestinal cancers

On 29 May 2020, the US Food and Drug Administration (FDA) approved atezolizumab in combination with bevacizumab (TECENTRIQ and AVASTIN, Genentech Inc.) for patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Efficacy was investigated in IMbrave150 (NCT03434379), a multicentre, international, open-label, randomised trial in patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy. A total of 501 patients were randomised (2:1) to receive either atezolizumab 1200 mg as an intravenous infusion (i.v.) followed by bevacizumab 15 mg/kg i.v. on the same day, every 3 weeks, or sorafenib orally twice daily.

The main efficacy outcome measures were overall survival (OS) and independent review facility (IRF)-assessed progression-free survival (PFS) per RECIST v1.1. Additional efficacy outcome measures were IRF-assessed overall response rate (ORR) per RECIST v1.1 and mRECIST.

Median OS was not reached in the patients who received atezolizumab plus bevacizumab and was 13.2 months (95% confidence interval [CI] 10.4, NE) in the patients who received sorafenib (hazard ratio [HR] 0.58; 95% CI 0.42, 0.79; p = 0.0006).

Estimated median PFS was 6.8 months (95% CI 5.8, 8.3) vs. 4.3 months (95% CI 4.0, 5.6), respectively (HR 0.59; 95% CI 0.47, 0.76; p < 0.0001).

The ORR per RECIST v1.1 was 28% (95% CI 23, 33) in the atezolizumab plus bevacizumab group compared with 12% (95% CI 7,17) in the sorafenib group (p < 0.0001). The ORR per mRECIST was 33% (95% CI 28, 39) vs. 13% (95% CI 8, 19), respectively (p < 0.0001).

The most common adverse reactions (reported in ≥20% of patients) with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma were hypertension, fatigue and proteinuria.

The recommended atezolizumab dose is 1,200 mg, followed by 15 mg/kg bevacizumab on the same day every 3 weeks. If bevacizumab is discontinued, atezolizumab should be given either as 840 mg every 2 weeks, 1,200 mg every 3 weeks, or 1,680 mg every 4 weeks.

Full prescribing information for TECENTRIQ is available here and for AVASTIN here.

FDA collaborated with the Australian Therapeutic Goods Administration (TGA), Health Canada, and Singapore’s Health Sciences Authority (HSA) on the review of the atezolizumab application as part of Project Orbis. FDA approved this application nearly two months ahead of schedule. The review of the atezolizumab application is ongoing for the Australian TGA, Health Canada and Singapore’s HSA.

This review used the Real-Time Oncology Review, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.

These applications were granted priority review and atezolizumab and bevacizumab received breakthrough designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact FDA’s Oncology Center of Excellence Project Facilitate. 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings